Evolus reported Q2 2026 revenue of $84.08 million, beating consensus and prompting a raise to full-year guidance. The beat reflects sustained demand for Jeuveau, the company's rapid-onset neuromodulator, which continues to gain share in the toxin market through aggressive rebate positioning and practice-friendly dosing protocols.
Business & M&A
Evolus Tops Q2 Revenue Forecast, Raises 2026 Outlook
Jeuveau momentum accelerates; injectable platform becomes the core growth engine.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Injectable platform is becoming the real moat for Evolus.
The injectable platform is now the real moat. Evolus has shifted from device-dependent growth to a dual-revenue model anchored by Jeuveau, which carries higher gross margins than hardware and locks in recurring customer relationships. The guidance raise signals confidence in sustained toxin uptake and suggests the company sees no near-term competitive pressure from Revance's Daxxify or other entrants. For practices, this means Jeuveau rebate terms will likely remain competitive through 2026.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.